Wall Street analysts forecast that GlycoMimetics Inc (NASDAQ:GLYC) will report earnings per share (EPS) of ($0.36) for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for GlycoMimetics’ earnings, with estimates ranging from ($0.40) to ($0.33). GlycoMimetics posted earnings per share of ($0.26) in the same quarter last year, which indicates a negative year-over-year growth rate of 38.5%. The business is expected to report its next earnings results before the market opens on Thursday, August 8th.

On average, analysts expect that GlycoMimetics will report full year earnings of ($1.18) per share for the current fiscal year, with EPS estimates ranging from ($1.61) to ($0.21). For the next financial year, analysts expect that the company will report earnings of ($1.25) per share, with EPS estimates ranging from ($1.82) to ($0.46). Zacks’ earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for GlycoMimetics.

GlycoMimetics (NASDAQ:GLYC) last released its quarterly earnings data on Thursday, May 2nd. The biotechnology company reported ($0.33) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.01.

GLYC has been the subject of a number of recent research reports. BidaskClub raised shares of Xilinx from a “hold” rating to a “buy” rating in a research report on Wednesday, July 24th. Cowen set a $150.00 price objective on Tesla and gave the company a “sell” rating in a research note on Friday, May 3rd. Piper Jaffray Companies set a $80.00 price objective on Canopy Growth and gave the company a “buy” rating in a research note on Friday, April 12th. HC Wainwright set a $5.00 price objective on SuperCom and gave the company a “buy” rating in a research note on Friday, April 12th. Finally, Zacks Investment Research cut GENEL ENERGY PL/ADR from a “hold” rating to a “sell” rating in a research note on Thursday, July 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $23.00.

Several institutional investors and hedge funds have recently modified their holdings of the company. FMR LLC lifted its holdings in GlycoMimetics by 10.3% in the first quarter. FMR LLC now owns 3,896,740 shares of the biotechnology company’s stock valued at $48,553,000 after acquiring an additional 365,096 shares during the period. Dimensional Fund Advisors LP increased its holdings in shares of GlycoMimetics by 58.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 617,420 shares of the biotechnology company’s stock valued at $5,847,000 after purchasing an additional 228,664 shares during the last quarter. Asymmetry Capital Management L.P. acquired a new position in shares of GlycoMimetics in the first quarter valued at $1,707,000. Candriam Luxembourg S.C.A. acquired a new position in shares of GlycoMimetics in the first quarter valued at $915,000. Finally, Squarepoint Ops LLC grew its stake in shares of GlycoMimetics by 259.3% in the fourth quarter. Squarepoint Ops LLC now owns 84,115 shares of the biotechnology company’s stock valued at $797,000 after acquiring an additional 60,701 shares in the last quarter.

Shares of GlycoMimetics stock traded down $0.16 during trading on Monday, reaching $9.02. The company’s stock had a trading volume of 420,300 shares, compared to its average volume of 276,594. The firm’s 50-day moving average price is $11.44. The firm has a market capitalization of $396.39 million, a price-to-earnings ratio of -7.64 and a beta of 2.47. GlycoMimetics has a 52 week low of $8.29 and a 52 week high of $17.07. The company has a debt-to-equity ratio of 0.02, a quick ratio of 23.88 and a current ratio of 23.88.

About GlycoMimetics

GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company's advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and is in a Phase III clinical trial, conducted by its strategic collaboration with Pfizer Inc It is also developing uproleselan, an E-selectin antagonist that is evaluated in a Phase I/II clinical trial as a potential treatment for acute myeloid leukemia (AML), as well as Phase III trial to treat relapsed/refractory AML.

Featured Article: What is an SEC Filing?

Get a free copy of the Zacks research report on GlycoMimetics (GLYC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for GlycoMimetics (NASDAQ:GLYC)

Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.